Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies

European Journal of Haematology
R K MalladiT J Littlewood

Abstract

We report the use of reduced-intensity conditioning (RIC)-matched sibling allogeneic bone marrow stem cell transplantation as a method of establishing a graft-vs.-leukaemia (GvL) effect against myeloid disorders using a fludarabine-melphalan protocol without the use of T-lymphocyte-depleting antibodies. The 16 patients in this group had predominantly poor-risk acute myeloid leukaemia (AML) (n=10), AML/myelodysplasia (MDS) (n=2) and MDS (n=4). All but one patient achieved full haematopoietic engraftment. Thirteen of 16 patients are alive and in continued complete remission on completion of this study with a median follow-up of 426 d (range 83-1524). The actuarial 4 yr disease-free and overall survival is 79% for both. Only one patient relapsed following transplant, giving a relapse rate of 6% during the study period. The treatment-related mortality was 13% (n= 2). Overall, acute graft-vs.-host disease (GvHD) occurred in 53% (8/15), with acute GvHD grade II or above occurring in 47% (7/15). In the 13 evaluable patients, chronic GvHD occurred in 46% (6/13), with this being extensive in three patients. These results suggest that a GvL effect can be delivered against poor-risk myeloid disorders with a low non-relapse mortality using...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Sep 13, 1979·The New England Journal of Medicine·E D ThomasP L Weiden
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Dec 1, 1994·Leukemia & Lymphoma·P R Johnson, J A Yin
Jul 1, 1994·The Pediatric Infectious Disease Journal·L GuerreroL K Pickering
Apr 15, 1994·Annals of Internal Medicine·R P GaleM M Bortin
Nov 26, 1999·Cancer·H D Preisler
Aug 11, 2001·Bone Marrow Transplantation·D S RitchieA P Grigg
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharine BransonStephen Mackinnon
Oct 18, 2002·Blood·José A Pérez-SimónUNKNOWN Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke

❮ Previous
Next ❯

Citations

Oct 25, 2006·Annals of Hematology·Koichiro MinauchiTakao Koike
Mar 3, 2009·Bone Marrow Transplantation·T Kindwall-Keller, L M Isola
Sep 9, 2009·British Journal of Haematology·Olle RingdénMichael Uhlin
Jun 9, 2006·Blood Reviews·Wendy IngramGhulam J Mufti
Aug 28, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ulas D BayraktarStefan O Ciurea
Sep 27, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vikas GuptaThomas Kiss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.